A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

NCT02242656 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Transfer of IND to new marketing authorization holder

Conditions

Short Bowel Syndrome
Short Gut Syndrome
SBS
Short Bowel
Short Gut

Interventions

DRUG: Opium Tincture USP Deodorized
DRUG: Opium Tincture USP Deodorized

Sponsor

Marathon Pharmaceuticals, LLC